Artelo Biosciences Inc Stock Price, News & Analysis

Artelo Biosciences presented promising new data for its FABP5 inhibitor ART26.12 at the British Pain Conference, showing favorable comparison to naproxen in treating osteoarthritis pain. In a surgical rat model study, ART26.12 demonstrated dose-responsive analgesic effects that were sustained over 28 days, improving weight-bearing ability in affected limbs. The drug candidate, currently in human trials, is being developed as a non-opioid, non-steroidal treatment for chemotherapy-induced peripheral neuropathy and potentially chronic osteoarthritis pain. ART26.12's effectiveness matched naproxen, a first-line therapy known for serious side effects with chronic use. This development is significant given that osteoarthritis affects 606.9 million people globally, including 32 million in the U.S., causing chronic pain, reduced mobility, and decreased quality of life.

Artelo Biosciences (NASDAQ: ARTL) highlights a new independent review paper published in Neurobiology of Disease that validates their FABP inhibitor program for anxiety and depression treatment. The paper, co-authored by Dr. Steven Laviolette and researchers from the University of Western Ontario, provides evidence that FABP5, FABP3, and FABP7 are crucial in regulating lipid trafficking and neuroinflammatory signaling. Artelo's clinical-stage candidate ART26.12, which targets FABP5, has completed enrollment in a Phase 1 Single Ascending Dose study with nearly 50 healthy volunteers. The company expects to announce data this quarter and results from a food effect study this summer. The research suggests that FABP5 inhibition can increase anandamide levels and produce anxiety-reducing and antidepressant effects without typical cognitive side effects.

Artelo Biosciences (NASDAQ: ARTL) reported its Q1 2025 financial results and provided updates on its clinical pipeline. The company highlighted progress across three key programs: ART26.12, the first selective FABP5 inhibitor in clinical trials, completed Phase I enrollment with data expected in Q2 2025; ART27.13's Phase 2 CAReS study in cancer anorexia-cachexia syndrome with initial data expected in Q3 2025; and ART12.11, a proprietary cannabidiol cocrystal tablet showing improved pharmacokinetics versus Epidiolex®.

Financial results showed R&D expenses of $1.4M (vs $1.5M in Q1 2024), G&A expenses of $1.0M (vs $1.1M), and a net loss of $2.4M ($0.72 per share). Cash position stood at $0.7M, with an additional $0.9M raised through convertible notes in May 2025.

Artelo Biosciences (Nasdaq: ARTL) has published new research in the Journal of Investigative Dermatology demonstrating the effectiveness of ART26.12, their FABP5 inhibitor, in treating psoriasis. The study shows that ART26.12, an orally active small-molecule drug, achieved comparable results to immunomodulatory drugs in both in vitro and in vivo psoriasis models.

The research highlights that FABP5, first discovered in psoriasis tissue in the 1990s, is highly expressed in skin and immune cells and plays a important role in skin cell homeostasis. Pre-clinical studies suggest ART26.12 may offer a less costly and safer treatment approach for psoriasis compared to existing options.

The company has completed enrollment for its Phase 1 Single Ascending Dose study of ART26.12 in healthy volunteers, with data expected to be announced in the current quarter.

Artelo Biosciences (NASDAQ: ARTL) has announced that Lead Medicinal Chemist Myles Osborn will present at the 4th ACE Drug Discovery Summit in London on April 3, 2025. The presentation, scheduled for 12:30pm BST, will focus on analyzing multiple datasets regarding Fatty Acid Binding Protein 5 (FABP5) inhibition across various disease models.

The presentation, titled 'Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications,' will explore how FABP5 inhibition affects cellular communication pathways. Research has shown promising activity in treating neuropathic pain, osteoarthritis, cancer, and cancer bone pain.

The company's lead FABP5 inhibitor, ART26.12, is currently in Phase 1 Single Ascending Dose study with healthy volunteers, with data expected in Q2 2025.

Artelo Biosciences (NASDAQ: ARTL) has provided its fiscal 2024 year-end results and business update, highlighting multiple upcoming clinical milestones in 2025. The company reported a net loss of $9.8 million ($3.05 per share) for 2024, compared to $9.3 million in 2023.

Key financial metrics include R&D expenses of $6.0 million (up from $5.7M in 2023), G&A expenses of $4.1 million (down from $4.2M), and cash/investments position of $2.3 million as of December 31, 2024.

Three major clinical programs are advancing:

• ART26.12 (FABP5 inhibitor) Phase 1 study completion expected in Q2 2025
• ART27.13 Phase 2 CAReS trial for cancer anorexia with initial data due by Q2 2025
• ART12.11 (CBD-TMP cocrystal) targeting anxiety and depression, set for human trials in 2H 2025

Artelo Biosciences (NASDAQ: ARTL) has announced new nonclinical results for ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). The findings, presented at the International Medical Cannabis Conference in Switzerland, demonstrated that ART12.11 tablets achieved CBD and metabolite exposure levels similar or greater to equivalent doses of Epidiolex®, the only FDA-approved CBD therapy.

The company's tablet formulations, containing 100mg of CBD, show potential advantages including improved stability, easier dosing, lower cost-of-goods, and enhanced patient adherence. The cocrystallization approach addresses CBD's physical property challenges, enabling the manufacture of simple compression tablets with high drug loading. These results support ART12.11's potential as an alternative CBD formulation with improved pharmacokinetics and enhanced efficacy in nonclinical studies.

Artelo Biosciences (Nasdaq: ARTL) has announced its upcoming presentation at the International Medical Cannabis Conference (IMCCB-25) in Bern, Switzerland, scheduled for February 13-14, 2025. The company will present new data comparing their proprietary ART12.11 tablets to Epidiolex.

Professor Saoirse O'Sullivan, Vice President Translational Science at Artelo, will deliver a presentation titled 'A Cannabidiol Cocrystal (ART12.11) Tablet Has Comparable Pharmacokinetics to Epidiolex' on February 14, 2025. The presentation will focus on recent pharmacokinetic results from canine studies comparing ART12.11, a proprietary cocrystal composed of cannabidiol (CBD) and tetramethylpyrazine (TMP), with Epidiolex.

Artelo Biosciences specializes in modulating lipid-signaling pathways to develop treatments for cancer, pain, and dermatological or neurological conditions.

Artelo Biosciences (Nasdaq: ARTL) announced the successful completion of the first cohort in its Phase 1 study of ART26.12, a selective Fatty Acid Binding Protein 5 (FABP5) inhibitor. This marks a significant milestone in developing FABP inhibitors as a novel treatment approach for various conditions including cancer, pain, and neuropathies.

The study involved eight healthy volunteers, with the initial safety review completed. ART26.12 is the first-ever selective FABP5 inhibitor to enter clinical trials, targeting an intracellular protein involved in lipid signaling. This mechanism shows promise for managing painful neuropathies non-opioid treatments.

Preclinical studies have shown significant promise in models of Chemotherapy Induced Peripheral Neuropathy (CIPN), Diabetic Neuropathy, cancer bone pain, and osteoarthritis. Encouraged by the preclinical safety profile, Artelo aims to provide initial safety, pharmacokinetic, and biomarker data in the first half of 2025.

The next cohort in the Phase 1 study will offer further insights into the development of ART26.12. The results will help determine suitable doses for a multiple ascending dose study planned for the second half of 2025.